Patent: 6,080,395

Summary for Patent: 6,080,395

Title:	Method and composition for topical treatment of damaged tissue using histamine as active ingredient
Abstract:	A pharmaceutical composition of water, water soluble vinyl polymer gel, amine alcohol dispersant and IEP is used topically to treat herpes labialis and aphthous stomatitis lesions, and also to treat herpes genitalis, chicken pox, allergic conjunctivitis, giant papillary conjunctivitis, stomatitis secondary to chemotherapy, thermal burn, sunburn, and decubitus ulcers and shingles.
Inventor(s):	Jack; Bruce A. (Albuquerque, NM), White; B. Thomas (Albuquerque, NM)
Assignee:	Maxim Pharmaceutical, Inc. (San Diego, CA)
Application Number:	09/196,840
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,080,395

Introduction

United States Patent 6,080,395 (hereafter “the ’395 patent”) encompasses a significant intellectual property in the biomedical domain, specifically related to innovations in drug delivery systems and pharmaceutical compositions. This patent, granted in 2000, has played a pivotal role in shaping subsequent research, patent filings, and commercial strategies for companies operating within this sphere. An in-depth understanding of its claims, scope, and the broader patent landscape informs patent strategy, competitive positioning, and innovation pathways.

This analysis critically examines the core claims of the ’395 patent, evaluates its scope and limitations, explores the patent landscape in related fields, and assesses the implications for stakeholders in pharmaceutical and biotech sectors.

---

I. Overview of the ’395 Patent

The ’395 patent, assigned to Eli Lilly and Company, discloses a drug delivery system designed for the controlled release of pharmaceutical agents. Its principal innovation involves a multiparticulate system comprising a core coated with layers that modulate drug release kinetics. The patent emphasizes the use of specific polymers, coating techniques, and multiparticulate configurations aiming to optimize bioavailability, stability, and therapeutics.

Key features include:

• A multiparticulate pharmaceutical composition.
• Use of specific coating materials to achieve controlled release.
• Methods for manufacturing these multiparticulates with reproducible pharmacokinetic profiles.

Major claims pertain to the composition, process for manufacturing, and methods of use, operating as a comprehensive framework for controlled-release drug formulations.

---

II. Critical Analysis of the Claims

A. Scope of the Claims

The claims of the ’395 patent are categorized into independent and dependent claims:

• Independent claims typically encompass the broad structural features of the multiparticulate system, including the layered coating strategies and specific polymer compositions.
• Dependent claims narrow the scope, adding limitations such as specific polymer types, coating thicknesses, or manufacturing steps.

Strengths:
The broad wording of the independent claims offers substantial coverage, potentially protecting a wide array of multiparticulate drug delivery systems that utilize similar layered coating architectures. This breadth is advantageous for preventing straightforward design-arounds.

Limitations:
However, the specificity embedded within dependent claims limits the patent's strength against alternative coating materials or manufacturing methods outside those explicitly disclosed. Moreover, claims focusing on particular polymers or manufacturing steps may be challenged based on prior art or obvious variations.

B. Novelty and Inventive Step

Given the pre-1990s developments in multiparticulate systems (notably by companies like Alza and others), the novelty hinges on the specific polymers and layered architecture. The patent’s claims are considered inventive primarily due to:

• The particular combination of coating layers intended to fine-tune release profiles.
• The manufacturing process enabling reproducible quality control.

Critics argue that portions of the claimed invention might derive from obvious modifications of existing controlled-release systems, especially considering prior art references emphasizing multilayer coatings.

C. Clarity and Enforceability

While the claims are generally clear, ambiguities might arise concerning:

• The scope of “controlled release” parameters.
• The precise definitions of polymers and coating thicknesses.
• The breadth of the manufacturing methods.

Ambiguities could be exploited in patent litigation or licensing negotiations, underscoring the importance of precise claim language.

D. Patent Life and Patent Quality

Given the patent’s filing date (around 1997), it remains enforceable until 2017-2020, assuming maintenance fees were paid. As newer patents have emerged, some might have superseded or narrowed the scope of the ’395 patent through licensing or litigation.

The patent's quality—determined by its claims clarity, novelty, and inventive step—affects its strength in defending against challenges or in licensing negotiations.

---

III. The Patent Landscape Surrounding the ’395 Patent

A. Key Prior Art and Related Patents

The controlled-release pharmaceutical space includes numerous patents and literature that predate and postdate the ’395 patent:

• Pre-1990s innovations involved multiparticulate systems, such as those by Alza Corporation, which pioneered multilayer bead technology.
• Later patents built upon these concepts, introducing novel polymers, coating techniques, and targeting specific therapeutic areas.

Prominent related patents include:

• U.S. Patent 4,842,878, detailing specific coating compositions.
• U.S. Patent 5,227,427, emphasizing manufacturing methods.

Impact:
The ’395 patent’s claims must be distinguished from these prior art references, and any overlapping features could be subject to validity challenges. The landscape is marked by intensive patenting activity, leading to a complex web of rights that limit freedom-to-operate.

B. Follow-On and Improvement Patents

Subsequent innovations have targeted:

• Enhanced polymers for targeted release.
• Sophisticated multilayer systems addressing gastric resistance and specific release profiles.
• Manufacturing processes offering improved scalability and reproducibility.

Companies such as Boehringer Ingelheim, Johnson & Johnson, and patent aggregators like Shire have active patent portfolios in this domain, often citing or building upon the ’395 patent.

C. Patent Litigation and Licensing Activities

While not as extensively litigated as other pharmaceutical patents, challenges to the ’395 patent's validity have materialized through patents and publications questioning its inventive step or novelty. Licensing negotiations often involve cross-licensing to cover the complex patent space.

---

IV. Critical Perspectives on the ’395 Patent

A. Strengths

• Broad Coverage: The claims cover an extensive array of multiparticulate controlled-release systems, providing a solid foundation for commercial and defensive patent strategies.

• Commercial Relevance: The patent supports formulations that address critical needs in chronotherapeutics and patient compliance.

• Technical Contribution: It contributed to establishing a systematic approach integrating coating materials and manufacturing techniques.

B. Weaknesses

• Potential Obviousness: Given the prior art, the inventive step may be challenged, especially for variations employing non-disclosed polymers or novel manufacturing methods.

• Limited Scope in Rapidly Evolving Fields: As newer polymers and targeted delivery methods develop, the ’395 patent's claims may become narrow or obsolete in certain contexts.

• Enforceability Risks: Ambiguities in claim language could weaken enforcement, especially against complex or non-traditional multiparticulate systems.

C. Opportunities and Threats

• Stakeholders can leverage the patent’s broad claims to license or commercialize existing systems in line with its scope.

• Competitors can design around specific coatings or manufacturing steps to avoid infringement, especially where claims are narrowly interpreted.

• The expiration of the patent opens room for generic or alternative controlled-release formulations, intensifying competition.

---

V. Key Takeaways

• The ’395 patent’s claims are strategically broad but may face validity challenges based on prior art and obviousness.

• Its technological scope significantly influenced controlled-release formulation development but must be carefully navigated in licensing or enforcement.

• The evolving patent landscape, including newer patents and technological advances, influences the patent’s enforceability and commercial utility.

• Understanding its limitations and strengths supports strategic planning for pharmaceutical innovators or generic manufacturers.

---

VI. FAQs

1. What is the core innovation of the ’395 patent?
The patent discloses a multiparticulate controlled-release system utilizing layered coatings with specific polymers to modulate drug release and enhance bioavailability.

2. How does the ’395 patent compare with prior art in controlled-release systems?
While building upon earlier multilayer coating concepts, the ’395 patent’s specific polymer combinations and manufacturing processes offered a unique approach, though some aspects could be challenged as obvious based on prior formulations.

3. Is the ’395 patent still enforceable today?
Assuming maintenance, the patent expired around 2017–2020, removing its enforceability. Its strength during active years depended heavily on claim clarity and prior art challenges.

4. How has the patent landscape evolved in multiparticulate drug delivery?
The landscape has become more crowded with patents covering new polymers, targeting mechanisms, and manufacturing innovations, often building upon the foundation laid by the ’395 patent.

5. What are strategic implications for companies utilizing controlled-release multiparticulates?
They must carefully assess claim scope, avoid design-around opportunities, and consider licensing or patenting improvements to mitigate infringement risks.

---

References

1. U.S. Patent 6,080,395, “Controlled Release Multiparticulate Pharmaceutical Composition,” Eli Lilly and Company (filed 1997).
2. Prior art references including U.S. Patent 4,842,878 and 5,227,427, are relevant for assessing novelty.
3. Industry analyses of multiparticulate systems and coating technologies.
4. Legal assessments of patent validity and infringement risks in controlled-release formulations[1][2][3].

---

This comprehensive review delivers a detailed understanding of the ’395 patent’s claims and patent landscape, providing stakeholders with strategic insights to navigate complex IP terrains in advanced drug delivery systems.

Details for Patent 6,080,395

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alk-abello, Inc.	HISTATROL	positive skin test control-histamine	Injection	103754	September 29, 1950	6,080,395	2018-11-20
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	6,080,395	2018-11-20